Last reviewed · How we verify
Biodentin
At a glance
| Generic name | Biodentin |
|---|---|
| Also known as | Biodentin Pulpotomy |
| Sponsor | University of Maryland, Baltimore |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vital Pulp Treatment in Primary Teeth (PHASE4)
- A Comparative Clinical Study Assessing Dentin Thickness and Discoloration in Deep Carious Lesions Treated With Biodentine Alone Versus Diode Laser Pre-treatment Followed by Biodentine (NA)
- Deep Caries in Mature Teeth With Reversible Pulpitis (NA)
- Evaluation and Treatment of Crown Fractures Using the Modified Baysal Dental Trauma Index (NA)
- Outcome of Pulpotomy With MTA and Biodentin in Permanent Teeth With Caries Exposure (NA)
- Postoperative Pain After Full Pulpotomy With TheraCal PT, Biodentin, and MTA (NA)
- Outcome of NSRCT Versus VPT in Management of Teeth with Symptomatic Irreversible Pulpitis Associated with Apical Periodontitis (NA)
- Socket Preservation Using Biodentin Versus Xeno Graft for Single Rooted Teeth (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biodentin CI brief — competitive landscape report
- Biodentin updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI